CSPC Megalith Biopharmaceutical Co.,Ltd. $1093.HK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS34
PHASE 3 / 2-315
RECRUITING9
READOUTS ≤12 MONTHS8
READOUT SLIPPED >6 MO0%
Delay Index: of 5 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open CSPC Megalith Biopharmaceutical Co.,Ltd. on the live radar map → 📅 $1093.HK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SYS6010 NCT06927986 |
P3 | Recruiting | EGFR-mutated Locally Advanced or Metastatic NSCLC | 380 | 2026-07-30 |
| SYS6010 NCT07256509 |
P2 | Not yet recruiting | Non-Small Cell Lung Cancer | 120 | 2026-11-30 |
| SYNSTAR-02 NCT07376382 |
P3 | Not yet recruiting | NSCLC | 680 | 2026-12-12 |
| A zoster mRNA vaccine SYS6017 NCT07354659 |
P2 | Not yet recruiting | Herpes Zoster | 800 | 2027-03-10 |
| SYS6041 NCT07744763 |
P1/2 | Recruiting | Advanced Solid Tumors | 260 | 2027-03-28 |
| SYS6010 jnjection NCT06775236 |
P1/2 | Not yet recruiting | Advanced Solid Tumors; Breast Cancer | 410 | 2027-06-15 |
| SYS6045 NCT07122063 |
P1/2 | Active, not recruiting | Advanced Solid Tumors | 266 | 2027-07-30 |
| Recombinant Zoster Vaccine (CHO cell) SYS6052 NCT07892989 |
P1/2 | Not yet recruiting | Herpes Zoster | 496 | 2027-07-31 |
| SYS6010 injection NCT07633873 |
P3 | Not yet recruiting | Non-Small Cell Lung Cancer | 500 | 2027-09-30 |
| SYS6023 NCT07597629 |
P2 | Recruiting | Advanced Breast Cancer | 36 | 2027-11-30 |
| SYS6043 NCT07415863 |
P1/2 | Recruiting | Advanced/Metastatic Solid Tumors | 820 | 2027-12-30 |
| JMT101 NCT06989671 |
P2 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma | 430 | 2027-12-30 (+3 mo) |
| SYNSTAR03 NCT07442565 |
P3 | Not yet recruiting | Non-Small Cell Lung Cancer | 506 | 2027-12-30 |
| SYS6090 (Fixed Dose Level A) + bevacizumab NCT07750041 |
P1/2 | Not yet recruiting | Unresectable Advanced or Metastatic Colorectal Cancer | 260 | 2027-12-31 |
| SYS6002 NCT07230626 |
P3 | Not yet recruiting | Cervical Cancer | 412 | 2028-01-01 |
| SYS6041, bevacizumab NCT07714668 |
P2 | Recruiting | Ovarian Cancer; Recurrent Ovarian Cancer | 171 | 2028-04-30 |
| SYS6002 NCT07374549 |
P2 | Not yet recruiting | Advanced Urothelial Carcinoma | 100 | 2028-06-01 |
| SYS6010 injection NCT07254585 |
P2 | Recruiting | Head and Neck Squamous Cell Carcinoma | 110 | 2028-06-30 |
| SYS6010 NCT07758621 |
P3 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma | 340 | 2028-09-15 |
| SYS6026 NCT07702656 |
P2 | Not yet recruiting | High-grade Cervical Intraepithelial Lesions | 175 | 2028-09-30 |
| SYS6043 NCT07833735 |
P1/2 | Not yet recruiting | Advanced Solid Tumors | 400 | 2028-10-15 |
| Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043 NCT07879911 |
P3 | Not yet recruiting | Triple Negative Breast Cancer | 550 | 2028-11-30 |
| SYS6010 NCT07417735 |
P3 | Not yet recruiting | Locally Advanced/Metastatic/Recurrent ESCC | 436 | 2028-12-31 |
| SYS6006 NCT07622225 |
P1/2 | Not yet recruiting | Advanced Solid Tumors | 264 | 2028-12-31 |
| SYS6088 NCT07857135 |
P1/2 | Not yet recruiting | Advanced/Metastatic Solid Tumors | 140 | 2029-02-03 |
| SYS6010 NCT07406542 |
P3 | Not yet recruiting | Recurrent or Metastatic Breast Cancer | 400 | 2029-04-01 |
| SYS6062 NCT07897227 |
P1/2 | Not yet recruiting | Advanced Solid Tumors; Gastric Cancer (GC) | 260 | 2029-05-01 |
| SYS6002 NCT07526792 |
P3 | Not yet recruiting | Urothelial Carcinoma | 406 | 2029-06-01 |
| SYS6090 Injection + Bevacizumab Injection NCT07761286 |
P1/2 | Not yet recruiting | HCC - Hepatocellular Carcinoma | 288 | 2029-09-30 |
| SYS6010 NCT07672223 |
P3 | Recruiting | Non-small Cell Lung Cancer | 586 | 2029-09-30 |
| SYS6010 combined with Enlonstobart NCT07925021 |
P3 | Recruiting | Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma | 424 | 2029-10-01 |
| SYS6043 NCT07708753 |
P3 | Recruiting | Platinum-resistant Ovarian Cancer; Platinum-resistant Primary Peritoneal Cancer | 460 | 2029-10-01 |
| SYS6010+SG001+ physician's choice (Capecitabine or 5-FU) NCT07251062 |
P2/3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 737 | 2029-12-30 |
| SYS6010 NCT07924111 |
P3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 585 | 2029-12-30 |